Lung ultrasound role in the evaluation of the lung

There is an emerging evidence base and clinical experience using lung ultrasound (LUS) to evaluate a wide range of pulmonary conditions; whereas, historically, LUS was considered off-limits for lung imaging (1). LUS has recently shown its utility in the detection of a broad range of pathologies including modification of the structure of lung parenchyma from pulmonary oedema, pneumothorax, interstitial fibrosis, and pulmonary diseases characterized by a decrease in lung air content and by an alteration of tissue, air and fluid ratio (2). In these conditions, LUS may detect different artifacts depending on subpleural tissue alterations (3). In normal conditions, parietal and visceral pleura sliding may be detected together with the possible presence of A-lines that reflect the reverberations of the pleura (4). In the case of lung oedema or interstitial lung disease (ILD), both are characterized by the loss of peripheral lung aeration, and therefore the ultrasound beam is reflected creating reverberation artifacts called B lines (also known as “comet-tails”). According to expert recommendations from 2012, B-lines are defined as “discrete laser-like vertical hyperechoic reverberation artifacts arising from the pleural line, extending to the bottom of the screen without fading and moving synchronously with lung sliding” (5). Several studies and reviews have reported the presence of B-lines in cardiogenic pulmonary oedema, acute respiratory distress syndrome (ARDS), and ILD in connective tissue diseases (CTD) (1, 6-9). Although B-lines are a sonographic sign of an interstitial involvement, they may have different aspects and distribution, depending on the pathological subpleural process (cardiogenic edema, ARDS, fibrosis) (4). It is now well known that B-lines appear as diffuse either in cardiogenic edema and in ARDS. However, in ARDS they are frequently associated with an irregular, thickened pleural line, and to the possible presence of subpleural consolidation and areas of sparing (3). Therefore, LUS could help in the differential diagnosis between acute cardiogenic pulmonary oedema and ARDS; showing in ARDS the presence of an inhomogeneous alveolar-interstitial syndrome with spared areas, pleural line abnormalities and lung consolidations. ARDS is characterized by an impairment of the alveolar capillary membrane which leads to an alveolar involvement with ground glass (GG) opacities in the initial phase until the appearance of consolidation. These anatomical modifications may be reflected in the above described LUS findings that seem to be peculiar and strongly predictive of non-cardiogenic oedema also in the early phase (7). In addition, a recent study suggested the utility of LUS in the early investigation for pneumonia in patients with ARDS presenting to the emergency department. The authors reported the correlation of four LUS patterns to different degrees and severity of lung...
The role of CT in COVID-19 pneumonia

CT scans are widely considered as the current “gold standard” to diagnose COVID-19 pneumonia. A number of studies have identified that CT can identify abnormalities in the early phases, including the detection of subpleural, unilateral, and multifocal GG opacities, and with a slight predominance of lower right lobe. During the course of the disease, CT scans reveal a progression of lesions becoming bilateral, diffuse with a transition to consolidation (with or without pleural effusion). The decrease in GG opacities is associated with the predominance of a reticular pattern with bronchiectasis and irregular interlobular or septal thickening, signs of the development of lung fibrosis (23). These data suggest a crucial role for CT in diagnosis of patients with COVID-19 infection or of those with possible disease. However, the concordance between CT imaging and laboratory results remains unknown to date. In addition, a number of recent studies have reported potential limitations of CT imaging including (but not limited to) the sensitivity of early infection after symptom onset and specific CT features which appear to be related to infection over time (24). Therefore, the role of CT imaging in COVID-19 infection remains debated and needs more supportive evidence, in particular regarding its use in screening asymptomatic patients, also considering the radiation exposure (25).

The role of LUS in COVID-19 pneumonia

Given these data, the role of LUS in the evaluation and monitoring of patients with the novel COVID-19 pneumonia is emerging. The first cases of pneumonia caused by the novel coronavirus (SARS-CoV-2) breakout in Wuhan, Hubei (China) in December 2019 (26). It rapidly spread all over China and the world and at the end of January 2020, the World Health Organization (WHO) defined the new coronavirus a “Public Health Emergency of International Concern (PHEIC).” The COVID-19 was declared a pandemic on 11 March 2020 affecting all areas of the world, except the Antarctic continent and with particular incidence in Italy where it still represents a serious challenge to public healthcare structures.

The pathophysiology of COVID-19 pneumonia is complex. The lung injury in COVID-19 pneumonia is characterized by alveolar damage with edema, proteinaceous exudates, vascular congestion and initial reparative process in two patients subjected to lung lobectomies for cancer (27). In our paper the potential role of LUS in the diagnosis and management of COVID-19 pneumonia is discussed.

In this context, LUS can acquire relevance in COVID-19 pandemic, also considering the capacity to detect lung lesions before the development of hypoxemia in experimental ARDS models (28). In addition, LUS allows to perform the clinical examination and to acquire lung images by the same clinician with the possibility to cover the probe and decreasing the risk of exposure of health-care workers (29). In this context, recommendations for US transducer and equipment cleaning and disinfection in COVID-19 disease, have recently been published by the UK Intensive Care Society (30). Moreover, the possibility to have a radiation-free imaging technique may play an important role in the evaluation of peculiar categories of patients as in pregnant women. In this context, Moro F et al recently proposed a systematic approach for obstetricians/gynaecologists to perform LUS in pregnant women (31). Recently a case report of a 32-year-old woman, with 35+3-week singleton pregnancy, with COVID-19 infection has been described. Although she initially was afebrile and with a negative reverse transcription polymerase chain reaction (RT-PCR) result, the LUS already showed sign of lung involvement with thick B-lines bilaterally in particular in the basal posterior areas. Patient initially refused hospitalization and went to home against medical advice. Two-days later she still was afebrile, but she complained worsened dyspnoea. LUS was repeated with the detection of imaging findings consistent with interstitial involvement: diffuse thick B-lines and the following CT scan showed signs of COVID-19 pneumonia (32). This case confirmed the vital role of LUS in certain categories of COVID-19 patients in which avoiding radiation exposure from plain radiography is crucial. This case also identified the critical role of imaging investigations in the management of COVID-19 infection as RT-PCR testing can be negative in the early phase, despite the patient having significant lung involvement.

A recent manuscript reported the experience on the use of LUS in 20 patients with COVID-19. The authors reported that, LUS features correlated with CT findings, in particular, the presence of B-lines (multifocal, discrete or confluent) corresponded to CT GG areas and where B-lines had become confluent, CT mirrored pulmonary infiltrating shadows. Pleural effusion was rare, whereas, LUS may detect consolidations when they extend to the pleural surface. In addition, the authors reported focal B-lines in the early stage of the disease, whereas irregular B-lines and thickening of the pleural line were seen in patients with fibrosis and alveolar interstitial syndrome in more severe and progressive stages (33). In COVID-19 pneumo-
nia, as in all lung diseases, the main limitation of LUS is the detection of pulmonary alterations deep within the lung parenchyma which do not extend to the pleural surface. LUS remains crucial in the detection of all conditions which are characterised by pleural or subpleural tissue alterations and it may be of major utility in the management of COVID-19 patients (33). Recently, a case of a young man with COVID-19 pneumonia who was evaluated by LUS in 12 thorax areas has been reported. Pleural line abnormalities, B-lines, subpleural consolidations, areas of “white lung” and spared areas showing signs of interstitial-alveolar involvement, have been described (34). These data highlight a potential crucial role for LUS in the identification of lung involvement in COVID-19 as this examination allows a rapid assessment and, being radiation-free, it can be repeated regularly (i.e. within 12-24 hours) (33, 34). In a recent review, typical sonographic findings have been identified in different COVID-19 pneumonia phases. In the pre-disease or in the moderate phase, B-lines are clearly visible, may be adjacent to normal areas with or without small consolidations. In the severe phase, the number of B-lines increases and involves other areas of lung with the involvement of upper and anterior areas and they may become coalescent, and also consolidations may increase in both number and size. The critical phase of COVID-19 pneumonia is characterized by extensive coalescent B-lines with a significant alveolar interstitial syndrome in the posterior-basal areas of lungs (35). LUS may also find a place in the assessment of severity and progression of lung involvement during the infection. In this context, the use of a LUS score in the evaluation of COVID-19 patients has been recently proposed (36). Patients were evaluated by LUS in three different areas: anterior, lateral and posterior and in each area both superior and inferior segments were analysed. The adopted scoring system assigned one point to the presence of B-lines that when confluent with the appearance of the “white lung” image achieved two points; the presence of consolidation was scored as 3 points. The increase of the score reflected the decrease in lung aeration and the progression of lung severity, suggesting LUS a good examination tool to monitor patient course reducing the use of CT scans and plain radiographs. These data suggest the crucial role of LUS in closely following the patient trajectory in COVID-19 pneumonia which correlates with a worsening of lung involvement (36). The possibility to follow-up patients by LUS could allow clinicians to choose...
the more appropriate therapy according to lung severity and evolution of the disease. In this context, a LUS score could have the potential to grade the “severity” of COVID-19 pneumonia through scanning of 12 lung areas (six on each hemithorax) with a maximum score of 36. Previous studies have already demonstrated the potential utility of this score to guide strict follow-up of patients in the assessment of weaning from mechanical ventilation (normal pattern without significant B-lines=0 points; number of B-Lines ≥ 3 per rib space=1 point; presence of coalescent B-lines=2 points; consolidations=3 points) (37). It could be anticipated that in COVID-19 patients this score could allow the monitoring of the progression of lung involvement and/or the response to therapy as well as the need of ventilation technique, prone positioning, or changes in treatment in case of clinical worsening (35).

Therefore, these emerging data, together with the previous LUS findings in a broad range of pathologies with similar aspects of lung disease (ARDS, ILD and pneumonia), strongly support the potential rationale for LUS evaluation in the diagnosis and follow-up of COVID-19 lung involvement. COVID-19 clinical presentation can be widely heterogeneous and LUS could be useful in detecting pneumonia in patients with suspicious symptoms as fever and/or cough with a leading role in the triage of symptomatic subjects. LUS also has a large emerging role in prognostic stratification, which could allow the monitoring of response to therapeutic intervention such as change in treatments or to prone position (28, 33). LUS may be an invaluable tool to allow the identification of the earliest phases of interstitial damage. These include multiple B-lines, initially separated and after coalescent, in the posterior inferior lung areas. In a subsequent phase of pneumonia, B-lines extend to the anterior areas of the same lobes becoming coalescent posteriorly. This trend may explain the use of the prone position also in the earlier phases, marking the possible strategic role of LUS in patients’ monitoring. Therefore, LUS may acquire a strategic role also in the earlier phase of the infection, when CT pathological findings are rarer, occurring at a later stage during the disease, including with the appearance of severe features as consolidations, “crazy-paving” pattern, and “revere halo” sign (24). In these earlier stages, patients may be subjected to LUS that can be repeated after 12 or 24 hours when required and/or integrated with a CT scan if LUS findings are not sufficient to answer the clinical query or patient’s symptoms (33). The current utility of LUS in COVID-19 pneumonia are summarized in Table 1, and as reported the 12-zone LUS assessment is the more used scanning technique allowing a comparison between two examinations to better quantify and compare changes in time (35).

Conclusion

LUS has showed a promised potential role in the diagnosis and in monitoring of progression and evolution of COVID-19 infection. Recent data have suggested that LUS may be important in the follow-up of COVID-19 pneumonia patients through the scoring of sonography findings which appear to correlate with CT scan alterations according to the different phases and severity of lung involvement. Emerging data from the assessment of COVID-19 pneumonia by LUS could help with the management of other lung disorders as ILD in CTDS. In these diseases, LUS has already been investigated in the screening and detection of the modifications of the lung parenchyma due to ILD. In the future, the adoption of a LUS score system in CTDS could also be crucial in routine clinical practice to detect the evolution of ILD from GG opacities to more severe abnormalities.

Conflict of Interest: The authors have no conflict of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

References

1. Gargani L. Lung ultrasound: A new tool for the cardiologist. Cardiovasc Ultrasound 2011; 7: 6. [Crossref]
2. Soldati G, Smargiassi A, Inghingolo R, Sher S, Nenna R, Valente S, et al. Lung ultrasonography may provide an indirect estimation of lung porosity and airspace geometry. Respiration 2014; 88: 458-68. [Crossref]
3. Islam M, Levitus M, Eisen L, Shiloh AL, Fein D. Lungs of patients with interstitial lung disease: A literature review. Eur Respir J 2007; 30: 18-28. [Crossref]
4. Soldati G, Smargiassi A, Inghingolo R, Sher S, Nenna R, Valente S, et al. Lung ultrasonography may provide an indirect estimation of lung porosity and airspace geometry. Respiration 2014; 88: 458-68. [Crossref]
5. Volpicelli G, Elbarbary M, Blaivas M, Lichtenstein DA, Mathis G, Kirkpatrick AW, et al. International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med 2012; 38: 577-91. [Crossref]
6. Jambrik Z, Gargani L, Adamicza A, Kaszki J, Varga A, Forster T, et al. B-Lines quantify the lung water content: A lung ultrasound versus lung gravimetry study in acute lung injury. Ultrasound Med Biol 2010; 36: 2004-10. [Crossref]
7. Copetti R, Soldati G, Copetti P. Chest sonography: A useful tool to differentiate acute cardio-genic pulmonary edema from Acute respiratory distress syndrome. Cardiovasc Ultrasound 2008; 6: 16-22. [Crossref]
8. Blanco PA, Ganciulli TF. Pulmonary edema assessed by ultrasound: Impact in cardiology and intensive care practice. Echocardiography 2016; 33: 778-87. [Crossref]
9. Wang Y, Gargani L, Barskova T, Forst DE, Matucci-Cerinic M. Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease: A literature review. Arthritis Res Ther 2017; 19: 206-11. [Crossref]
10. Sanjani A, Krishnan SV, Abraham SV, Palatty BU. Utility of point-of-care lung ultrasound for initial assessment of acute respiratory distress syndrome patients in the emergency department. J Emerg Trauma Shock 2019; 12: 248-53.
11. Mayo PH, Copetti R, Feller-Kopman D, Mathis G, Maury E, Mongodi S, et al. Thoracic ultrasonography: A narrative review. Intensive Care Med 2019; 45: 1200-11. [Crossref]
12. Gutierrez M, Tardella M, Rodriguez L, Mendoza J, Clavijo-Cornejo D, Garcia A, et al. Ultrasound as a potential tool for the assessment of interstitial lung disease in rheumatic patients. Where are we now? Radiol Med 2019; 124: 989-99. [Crossref]
13. Gutierrez M, Soto-Fajardo C, Pineda C, Alface-Rodriguez A, Terslev L, Bruyn G, et al. Ultrasound in the assessment of interstitial lung disease in systemic sclerosis: A systematic literature review by the OMERACT Ultrasound Group. J Rheumatol. 2019 July 1. doi: 10.3899/jrheum.180940. [Online ahead of print]. [Crossref]
14. Bourcier JE, Braga S, Garnier D. Lung ultrasound will soon replace chest radiography in the diagnosis of acute community-acquired pneumonia. Curr Infect Dis Rep 2016; 18: 43. [Crossref]
15. Perrone T, Quaglia F. Lung US features of severe interstitial pneumonia: case report and review of the literature. J Ultrasound 2017; 20: 247-9. [Crossref]
16. Rambhia SH, D’Agostino CA, Noor A, Villani R, Naidich JJ, Pellerito JS. Thoracic Ultrasound: Technique, applications, and interpretation. Curr Prob Diagn Radiol 2017; 46: 305-16. [Crossref]
17. Grimberg A, Shiguedaka DC, Atallah AN, Ajzen S, Iared W. Diagnostic accuracy of sonography for pleural effusion: Systematic review. Sao Paulo J Radiol 2016; 6: 16-22. [Crossref]
itoring of ventilator-associated pneumonia. Ann Transl Med 2018; 6: 418. [Crossref]

21. Gu C, Xie Y, Zheng T, Ren H, Wang G, Ren J. Predictive value of lung ultrasound score on weaning outcome in patients with intra-abdominal infection undergoing mechanical ventilation. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2020; 32: 94-8.

22. Dransart-Rayé O, Roldi E, Zieleskiewicz L, Guinot PG, Mojoli F, Mongodi S, et al. Lung ultrasound for early diagnosis of postoperative need for ventilatory support: A prospective observational study. Anaesthesia 2020; 75: 202-9. [Crossref]

23. Shi H, Han X, Jiang N, Yukun Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect Dis 2020; 4: 425-34. [Crossref]

24. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT findings in coronavirus disease-19 (COVID-19): Relationship to duration of infection. Radiology 2020 February 20. doi: 10.1148/radiol.2020200463. [Online ahead of print]. [Crossref]

25. Huang Y, Cheng W, Zhao N, Qu H, Tian J. CT screening for early diagnosis of SARS-CoV-2 infection. Lancet Infect Dis 2020 March 26. doi: 10.1016/S1473-3099(20)30241-3. [Online ahead of print]. [Crossref]

26. Zhu H, Wei L, Niu F. The novel coronavirus outbreak in Wuhan, China. Glob Health Res Policy 2020; 5: 6. [Crossref]

27. Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol 2020 February 28. doi: 10.1016/j.jtho.2020.02.010. [Online ahead of print]. [Crossref]

28. Soldati G, Smargiassi A, Inchigolo R, Buonsenso D, Perrone T, Briganti DF, et al. Is there a role for lung ultrasound during the COVID-19 pandemic? J Ultrasound Med. 2020 March 20. doi: 10.1002/jum.15284. [Online ahead of print]. [Crossref]

29. Buonsenso D, Pata D, Chiaretti A. COVID-19 outbreak: Less stethoscope, more ultrasound. Lancet Respir Med. 2020 March 20. doi: 10.1016/S2213-2600(20)30120-X. [Online ahead of print]. [Crossref]

30. Intensive Care Society. FUSIC COVID-19 guidance and resources. 20 March 2020. Available from: https://www.ics.ac.uk/ICS/ICS/FUSIC/FUSIC_COVID-19.aspx

31. Moro F, Buonsenso D, Moruzzi MC, Inchigolo R, Smargiassi A, Demi L, et al. How to perform lung ultrasound in pregnant women with suspected COVID-19 infection. Ultrasound Obstet Gynecol. 2020 March 24. doi: 10.1002/uog.22028. [Online ahead of print]. [Crossref]

32. Kalafat E, Yaprak E, Cinar G, Varli B, Ozsik S, Uzun C, et al. Lung ultrasound and computed tomographic findings in pregnant woman with COVID-19. Ultrasound Obstet Gynecol. 2020 April 6. doi: 10.1002/uog.22034. [Online ahead of print]. [Crossref]

33. Peng QY, Wang XT, Zhang LN, Chinese Critical Care Ultrasound Study Group (CCUSG). Findings of lung ultrasonography of novel coronavirus pneumonia during the 2019-2020 epidemic. Intensive Care Med 2020 March 12. doi: 10.1007/s00134-020-05996-6. [Online ahead of print]. [Crossref]

34. Buonsenso D, Piano A, Raffaelli F, Bonadia N, de Gaetano Donati K, Franceschi F. Point-of-Care Lung Ultrasound findings in novel coronavirus disease-19 pneumonia: A case report and potential applications during COVID-19 outbreak. Eur Rev Med Pharmacol Sci 2020; 24: 2776-80.

35. Smith MJ, Hayward SA, Innes SM, Miller A. Point-of-care lung ultrasound in patients with COVID-19 - a narrative review. Anaesthesia. 2020 April 10. doi: 10.1111/anae.15082. [Online ahead of print]. [Crossref]

36. Vetrugno L, Bove T, Orso D, Barbariol F, Bassi F, Boero E, et al. Our Italian experience using lung ultrasound for identification, grading and serial follow-up of severity of lung involvement for management of patients with COVID-19. Echocardiography 2020 April 1. doi: 10.1111/echo.14664. [Online ahead of print]. [Crossref]

37. Via G, Storti E, Gulati G, Neri L, Mojoli F, Braschi A. Lung ultrasound in the ICU: From diagnostic instrument to respiratory monitoring tool. Minerva Anestesiol 2012; 78: 1282-96.